NextPlat (NASDAQ:NXPL) Upgraded by Litchfield Hills Research to Strong-Buy Rating

Litchfield Hills Research upgraded shares of NextPlat (NASDAQ:NXPL) to a strong-buy rating in a report issued on Wednesday morning,Zacks.com reports.

Separately, Weiss Ratings upgraded shares of NextPlat from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, May 11th. One analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $11.00.

NextPlat Price Performance

Shares of NASDAQ NXPL opened at $6.48 on Wednesday. The company has a current ratio of 2.56, a quick ratio of 2.12 and a debt-to-equity ratio of 0.05. The company has a market capitalization of $17.56 million, a price-to-earnings ratio of -1.50 and a beta of 1.90. NextPlat has a twelve month low of $3.38 and a twelve month high of $11.10. The business has a 50 day simple moving average of $6.35 and a 200-day simple moving average of $5.93.

NextPlat (NASDAQ:NXPL) last released its quarterly earnings data on Thursday, May 14th. The company reported ($0.42) EPS for the quarter. NextPlat had a negative return on equity of 58.05% and a negative net margin of 23.14%.The business had revenue of $9.86 million during the quarter.

Institutional Investors Weigh In On NextPlat

An institutional investor recently bought a new stake in NextPlat stock. Citadel Advisors LLC bought a new stake in NextPlat Corp. (NASDAQ:NXPL) during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 48,176 shares of the company’s stock, valued at approximately $40,000. Citadel Advisors LLC owned about 0.19% of NextPlat as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 1.30% of the company’s stock.

About NextPlat

NextPlat Corp operates as a healthcare and e-commerce company in Europe, North America, South America, the Asia and Pacific, and Africa. The company operates full-service retail specialty services pharmacies that provides prescription pharmaceuticals prescription pharmaceuticals, third-party administration, risk and data management services, compounded medications, tele-pharmacy services, anti-retroviral medications, medication therapy management, contracted pharmacy services, and health practice risk management to healthcare organizations and providers, as well as supplies prescription medications to long-term care facilities.